Tech Company M&A Transactions
Abide Therapeutics Acquisition
Abide Therapeutics was bought by Lundbeck. The transaction occurred on 5/7/2019. The transaction price was $400 million.
Transaction Overview
Company Name
Acquired By
Announced On
5/7/2019
Transaction Type
M&A
Amount
$400,000,000
M&A Terms
Under the terms of the agreement, Lundbeck may pay USD 250 million (approximately DKK 1.65 billion) upfront with a commitment to pay future development and sales milestones to the group of current owners of up to USD 150 million (approximately DKK 1 billion). This acquisition provides Lundbeck a novel discovery platform and a U.S.-based research hub.
Company Information
Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
10835 Road to the Cure 250
San Diego, CA 92121
USA
San Diego, CA 92121
USA
Phone
Website
Email Address
Overview
Realizing the therapeutic potential of novel serine hydrolase inhibitors to yield drugs for treatment of diseases in areas of unmet medical need.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Alan Ezekowitz
Chief Financial Officer
Stan Blackburn
Chief Financial Officer
Sapna Srivastava
Chief Medical Officer
Chan Beals
VP - Operations
Julianne Hunt
VP - R & D
Gary O'Neill
Browse more venture capital transactions:
Prev: 5/7/2019: Carta venture capital transaction
Next: 5/7/2019: Noom venture capital transaction
Share this article
Where The Data Comes From
Our team works diligently to report on tech company VC transactions. VC transactions on this site are sourced from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs